Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up.
Study Type
OBSERVATIONAL
Enrollment
1,000
all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
Alexandre
Caen, Normandy, France
RECRUITINGOccurrence of major cardiovascular events and death of any cause at 1 year
Occurrence of death of any cause, cardiovascular death, heart failure, stroke, myocardial infarction in active cancer patients with atrial fibrillation.
Time frame: from inclusion in the registry to 1 year of follow-up
Occurrence of major cardiovascular events and death of any cause at 1 year in prevalent and incident AF patients
Occurrence of death of any cause, cardiovascular death, heart failure, stroke, myocardial infarction in active cancer patients according to the AF type (prevalent or incident).
Time frame: from inclusion in the registry to 1 year of follow-up
Description of the population of active cancer patients experiencing atrial fibrillation (in both prevalent and incidence AF patients).
Description of the population of active cancer patients experiencing atrial fibrillation. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
Time frame: at the inclusion in the registry
Description of the management of atrial fibrillation in cancer patients (in both prevalent and incidence AF patients).
Description of the management (anticoagulants, rhythm or rate control) of atrial fibrillation in cancer patients
Time frame: from inclusion in the registry to 1 year of follow-up
Description of the population of active cancer patients having a major cardiovascular event
Description of the population of patients having a major cardiovascular event among cancer patients experiencing atrial fibrillation
Time frame: from inclusion in the registry to 1 year of follow-up
Identifying risk factors associated with major cardiovascular events and all cause mortality occurrence
Identifying risk factors (clinical, EKG, biological, echocardiography) of major cardiovascular events and all cause mortality in cancer patients experiencing atrial fibrillation
Time frame: from inclusion in the registry to 1 year of follow-up
Identifying factors associated with atrial fibrillation recurrence
Identifying factors (clinical, EKG, biological, echocardiography) of atrial fibrillation recurrence in cancer patients
Time frame: from inclusion in the registry to 1 year of follow-up
Occurrence of major and clinically relevant non-major bleedings (2005 ISTH definition)
Occurrence of major and clinically relevant non-major bleedings in active cancer patients experiencing atrial fibrillation.
Time frame: from inclusion in the registry to 1 year of follow-up
Identifying risk factors associated with major and clinically relevant non-major bleedings (2005 ISTH definition)
Identifying risk factors (clinical, EKG, biological, echocardiography) of major and clinically relevant non-major bleedings in active cancer patients experiencing atrial fibrillation
Time frame: from inclusion in the registry to 1 year of follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.